Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684635 | 1.00 | ABCB1 (0.64) | ABCB1TAS1R3TAS1R1UTS2R | |
| SCHEMBL2682557 | 1.00 | ABCB1 (0.64) | ABCB1TAS1R3TAS1R1UTS2R | |
| SCHEMBL2681881 | 1.00 | ABCB1 (0.64) | ABCB1TAS1R3TAS1R1UTS2R | |
| SCHEMBL29727267 | 0.94 | ABCB1 (0.62) | ABCB1UTS2R | |
| SCHEMBL668804 | 0.94 | ABCB1 (0.62) | ABCB1UTS2R | |
| SCHEMBL667855 | 0.93 | ABCB1 (0.54) | ABCB1TAS1R3TAS1R1UTS2R | |
| SCHEMBL29684814 | 0.93 | ABCB1 (0.54) | ABCB1TAS1R3TAS1R1UTS2R | |
| SCHEMBL2681921 | 0.93 | ABCB1 (0.54) | ABCB1TAS1R3TAS1R1UTS2R | |
| SCHEMBL3766257 | 0.93 | ABCB1 (0.60) | ABCB1 | |
| SCHEMBL668812 | 0.92 | ABCB1 (0.66) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | claimed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | claimed |
| EP-3568474-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | Intrexon Corporation (US) | 2019-11-20 | — | — | EP | claimed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | claimed |
| WO-2018132494-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | INTREXON CORPORATION (US) | 2018-07-19 | — | — | WO | claimed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | claimed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | claimed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | claimed |
| US-20150240244-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2015-08-27 | — | — | US | claimed |
| US-9102648-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2015-08-11 | — | — | US | claimed |
| US-20140045903-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2014-02-13 | — | — | US | claimed |
| US-20130040389-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | Intrexon Coporation (US) | 2013-02-14 | — | — | US | claimed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | claimed |
| US-20120046322-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-02-23 | — | — | US | claimed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | claimed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | claimed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | claimed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-20260098063-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | PRECIGEN INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260035432-A1 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | PRECIGEN, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404306-B2 | Human papillomavirus vaccines and uses of the same | PRECIGEN, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250223320-A1 | HEPATITIS B VACCINES AND USES OF THE SAME | PRECIGEN, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12275772-B2 | ROR-1 specific chimeric antigen receptors and uses thereof | PRECIGEN, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12234261-B2 | Hepatitis B vaccines and uses of the same | PRECIGEN, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240368305-A1 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | PRECIGEN, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240263183-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | PRECIGEN, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4382913-A2 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | Precigen, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240173396-A1 | Human Papilloma Virus Vaccines and Uses of the Same for HPV Associated Diseases | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2024-05-30 | — | — | US | disclosed |
| US-11981746-B2 | MUC16 specific chimeric antigen receptors and uses thereof | PRECIGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11976134-B2 | MUC16 specific chimeric antigen receptors and uses thereof | PRECIGEN, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11946054-B2 | Modulating expression of polypeptides via new gene switch expression systems | PRECIGEN, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4274898-A2 | CHIMERIC RECEPTOR THERAPY | Precigen, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4251278-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | Precigen, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230279057-A1 | HEPATITIS B VACCINES AND USES OF THE SAME | PRECIGEN, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11692194-B2 | Modulating expression of polypeptides via new gene switch expression systems | PRECIGEN, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11608362-B2 | Hepatitis B vaccines and uses of the same | PRECIGEN, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2022150732-A2 | CHIMERIC RECEPTOR THERAPY | PRECIGEN, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220220187-A1 | CHIMERIC RECEPTOR THERAPY | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2022-07-14 | — | — | US | disclosed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022115470-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | PRECIGEN, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220153866-A1 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | PRECIGEN, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220153867-A1 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | PRECIGEN, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11319380-B2 | MUC16 specific chimeric antigen receptors and uses thereof | PRECIGEN, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210177902-A1 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2021-06-17 | — | — | US | disclosed |
| EP-3802615-A2 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Precigen, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210024586-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | PRECIGEN, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210015911-A1 | HEPATITIS B VACCINES AND USES OF THE SAME | PRECIGEN, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3762022-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | Precigen, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3762010-A1 | HEPATITIS B VACCINES AND USES OF THE SAME | Precigen, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200283778-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | PRECIGEN, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3568474-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | Intrexon Corporation (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2019173465-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | INTREXON CORPORATION (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173463-A1 | HEPATITIS B VACCINES AND USES OF THE SAME | INTREXON CORPORATION (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20180291384-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2018-10-11 | — | — | US | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018132494-A1 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | INTREXON CORPORATION (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2463269-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046322-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885TAS1R3 2234/4885TAS1R1 2333/4885 |
| US-20260035432-A1 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | RORB, ICOS, RORC | ABCB1 2759/4885TAS1R3 3559/4885TAS1R1 3066/4885 |
| US-20260098063-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | ANKRD54, POTEE, ANKK1 | ABCB1 4133/4885TAS1R3 1710/4885TAS1R1 2369/4885 |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885TAS1R3 2234/4885TAS1R1 2333/4885 |
| US-20130040389-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885TAS1R3 2234/4885TAS1R1 2333/4885 |
| US-20220220187-A1 | CHIMERIC RECEPTOR THERAPY | HAVCR2, PTPN6, PTPN18 | ABCB1 1438/4885TAS1R3 2987/4885TAS1R1 2984/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885TAS1R3 2234/4885TAS1R1 2333/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | ABCB1 692/4885TAS1R3 3889/4885TAS1R1 4166/4885 |
| US-20140045903-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR2C2, NR5A2 | ABCB1 1302/4885TAS1R3 2240/4885TAS1R1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.